Blinatumomab
Blinatumomab, sold under the brand name Blincyto, and known informally as blina,[5] is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells.[7] Blinatumomab was originally approved to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.In July 2014, the FDA granted breakthrough therapy status to blinatumomab for the treatment of acute lymphoblastic leukemia (ALL).A representative of Amgen said, "The price of Blincyto reflects the significant clinical, economic and humanistic value of the product to patients and the health-care system.
Monoclonal antibodyBi-specific T-cell engagerTargetDrugs.comMedlinePlusLicense dataDailyMedPregnancycategoryRoutes ofadministrationIntravenousDrug classAntineoplastic agentATC codeL01FX07Legal status ℞-onlyWARNINGPharmacokineticBioavailabilityMetabolismElimination half-lifeExcretionCAS NumberDrugBankChemSpiderFormulaMolar massbiopharmaceuticalPhiladelphia chromosomeacute lymphoblastic leukemiamonoclonal antibodiesbi-specific T-cell engagersantigenB cellsFood and Drug Administrationaccelerated approvalminimal residual diseaseT cellbispecific T-cell engagerT cellsmalignantT cell receptorcytotoxicBiologics License ApplicationpembrolizumabMemorial Sloan-Kettering Cancer CenterHealth CanadaAdopted NamesAmerican Medical AssociationThe Wall Street JournalTargeted cancer therapyantineoplastic agentsReceptor tyrosine kinaseHER1/EGFRCetuximabPanitumumabHER2/neuPertuzumabTrastuzumab+hyaluronidaseTrastuzumab emtansineTrastuzumab deruxtecanZanidatamabCatumaxomabEdrecolomabVEGF-ABevacizumabLeukemialymphomalymphoidGlofitamabElranatamabMosunetuzumabIbritumomabObinutuzumabOfatumumabRituximabTositumomabBrentuximabAlemtuzumabmyeloidGemtuzumab ozogamicinAmivantamabAtezolizumabAvelumabAxatilimabBelantamab mafodotinBermekimabCemiplimabCosibelimabDaratumumabDinutuximab betaDostarlimabDurvalumabElotuzumabEnfortumab vedotinEpcoritamabInotuzumab ozogamicinIpilimumabIsatuximabLoncastuximab tesirineMirvetuximab soravtansineMogamulizumabMoxetumomab pasudotoxNaxitamabNecitumumabNivolumab+relatlimabOlaratumabOportuzumab monatoxPolatuzumab vedotinRamucirumabRetifanlimabSacituzumab govitecanSerplulimabSugemalimabTafasitamabTalquetamabTarlatamabTeclistamabTislelizumabTisotumab vedotinToripalimabTremelimumabZenocutuzumabZolbetuximab